Sunshine Biopharma (SBFM) Change in Receivables (2015 - 2026)
Sunshine Biopharma (SBFM) posted Change in Receivables of $609601.0 for Q1 2026, up 1576.28% on a QoQ basis from -$41293.0 in Q4 2025, and up 242.87% year-over-year from $177792.0 in Q1 2025.
Sunshine Biopharma (SBFM) Change in Receivables (2015 - 2026) Analysis & Trends
Sunshine Biopharma's Change in Receivables history runs 10 years deep, the most recent figure standing at $609601.0 for Q1 2026.
- Quarterly Change in Receivables rose 242.87% year-over-year to $609601.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 16.2% YoY) and the FY2025 annual result came in at $116173.0, down 95.03% from the prior year.
- Change in Receivables was $609601.0 for Q1 2026 at Sunshine Biopharma, up from -$41293.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.8 million in Q2 2024 and bottomed at -$986986.0 in Q3 2024.
- A 5-year average of $261412.2 and a median of $127186.5 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables jumped 3166200.0% — and 2024, when it tumbled 1658.68%.
- Sunshine Biopharma's Change in Receivables stood at $532262.0 in 2022, then decreased by 10.63% to $475659.0 in 2023, then jumped by 113.81% to $1.0 million in 2024, then tumbled by 104.06% to -$41293.0 in 2025, then jumped by 1576.28% to $609601.0 in 2026.
- Business Quant data shows SBFM's Change in Receivables at $609601.0 in Q1 2026, -$41293.0 in Q4 2025, and $649850.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -38.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 609,601.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 609,601.00 |
| Mar 31, 2026 | 609,601.00 |
| Dec 31, 2025 | -41,293.00 |
| Dec 31, 2025 | -41,293.00 |
| Sep 30, 2025 | 649,850.00 |
| Sep 30, 2025 | 649,850.00 |
| Jun 30, 2025 | -65,711.00 |
| Jun 30, 2025 | -65,711.00 |
| Mar 31, 2025 | -426,673.00 |
| Mar 31, 2025 | -426,673.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | -986,986.00 |
| Sep 30, 2024 | -986,986.00 |
| Jun 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 536,261.00 |
| Mar 31, 2024 | 536,261.00 |
| Dec 31, 2023 | 475,659.00 |
| Dec 31, 2023 | 475,659.00 |